Fosun Pharma USA Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Fosun Pharma USA Inc Pharmaceutical Import Records from India — 2 Products, $450.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fosun Pharma USA Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $450.0K Trade | TransData Nexus

Fosun Pharma USA Inc

Pharmaceutical Importer · United States · Advanced Oncology Focus · $450.0K Total Trade · DGFT Verified

Fosun Pharma USA Inc is a pharmaceutical importer based in United States with a total trade value of $450.0K across 2 products in 2 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fosun Pharma USA Inc sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Fosun Pharma USA Inc — Import Portfolio & Supplier Network

Fosun Pharma USA Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fosun Pharma USA Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$428.3K	9	100.0%

Fosun Pharma USA Inc sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Fosun Pharma USA Inc Import?

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Oxaliplatin	Advanced Oncology	$250.0K	5	0.5%	19
2	Cisplatin	Oncology	$200.0K	4	1.6%	13

Fosun Pharma USA Inc imports 2 pharmaceutical products across 2 categories into United States totaling $450.0K.

Fosun Pharma USA Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fosun Pharma USA Inc., established in 2017 and headquartered in Princeton, New Jersey, is a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma). Fosun Pharma, founded in 1994 and headquartered in Shanghai, is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma USA operates as a U.S.-focused specialty pharmaceutical company, emphasizing innovation through strategic partnerships and internal research and development. The company markets a portfolio of specialty pharmaceutical injectable products and ophthalmics, aiming to build a collection of high-value, branded innovative products.

The leadership team at Fosun Pharma USA comprises experienced executives with strong backgrounds in both U.S. and European pharmaceutical companies, covering commercial operations and R&D. Notable leaders include CEO Wenjie Zhang, who also serves as Executive President and Co-CEO of the Innovative Medicines Division of Fosun Pharma, and Chief Commercial Officer Mousumi Sannigrahi, PhD, MBA.

2Distribution Network

Fosun Pharma USA's distribution network is centered at its headquarters in Princeton, New Jersey. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's strategic partnerships and innovative R&D model suggest a robust infrastructure designed to efficiently deliver pharmaceutical products across the United States. The focus on specialty pharmaceutical injectable products and ophthalmics indicates a distribution strategy tailored to meet the needs of healthcare providers and patients nationwide.

3Industry Role

In the United States pharmaceutical supply chain, Fosun Pharma USA Inc. functions primarily as a specialty pharmaceutical company, focusing on the development, marketing, and distribution of innovative injectable products and ophthalmics. The company's emphasis on strategic partnerships and internal R&D highlights its role in introducing high-value, branded innovative products to the U.S. market. This positions Fosun Pharma USA as a key player in addressing unmet medical needs through specialized pharmaceutical offerings.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fosun Pharma USA Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fosun Pharma USA's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $450,000 USD across nine shipments, all sourced from a single supplier, Gland Pharma Limited. This single-source dependency may present risks related to supply chain disruptions, quality control, and pricing negotiations. However, the consistent sourcing from Gland Pharma Limited suggests a stable and reliable relationship, potentially mitigating some of these risks. The portfolio concentration, with the top five products accounting for 100% of imports, indicates a focused product strategy, which could be advantageous in terms of quality control and market positioning.

2Supply Chain Resilience

The resilience of Fosun Pharma USA's Indian supply chain appears to be robust, given the consistent sourcing from Gland Pharma Limited. The focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, suggests a streamlined supply chain with specific quality and regulatory standards. However, the lack of publicly available information on backup suppliers and formulation diversity indicates potential vulnerabilities. The exposure to shipping routes and regulatory compliance of key suppliers are critical factors that could impact supply chain stability. Without detailed insights into these areas, a comprehensive assessment of supply chain resilience remains limited.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing pharmaceutical imports, ensuring that all imported drugs meet the required safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. For Indian generics, the FDA's Abbreviated New Drug Application (ANDA) pathway allows for the approval of generic drugs without the need for clinical trials, provided they demonstrate bioequivalence to the reference listed drug. This pathway facilitates the entry of generic drugs into the U.S. market, offering cost-effective alternatives to brand-name medications.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent, necessitating that all drugs comply with FDA regulations. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal recognition system for foreign GMP certifications, it evaluates foreign manufacturing facilities during inspections to ensure compliance with U.S. standards. Wholesale distribution authorization is also required, ensuring that entities involved in the distribution of pharmaceutical products are properly licensed and comply with federal and state regulations.

Fosun Pharma USA Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fosun Pharma USA's product strategy focuses on high-value, branded innovative products, particularly in the oncology therapeutic area. The company's lead oncology product, serplulimab, is expected to launch in 2026, following strong results from the international phase 3 study ASTRUM-005. This focus on oncology aligns with the global emphasis on addressing unmet medical needs in cancer treatment. The imports from India, including oxaliplatin and cisplatin, support this strategy by providing essential components for oncology therapies.

2Sourcing Profile

Fosun Pharma USA's sourcing strategy emphasizes the procurement of finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, from a single supplier, Gland Pharma Limited. This approach suggests a preference for suppliers that can provide high-quality, ready-to-market products. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for Fosun Pharma USA's sourcing needs.

3Market Positioning

Based on its product mix, Fosun Pharma USA serves the U.S. pharmaceutical market by focusing on specialty pharmaceutical injectable products and ophthalmics. The company's emphasis on high-value, branded innovative products positions it to cater to healthcare providers and patients seeking advanced treatment options, particularly in the oncology sector. This strategic focus enables Fosun Pharma USA to address specific therapeutic needs and differentiate itself in the competitive pharmaceutical landscape.

Seller's Guide — How to Become a Supplier to Fosun Pharma USA Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Fosun Pharma USA, especially if they can meet the company's stringent quality standards and regulatory requirements. Gaps in Fosun Pharma USA's current sourcing strategy, such as the reliance on a single supplier, may present opportunities for diversification and risk mitigation. Indian exporters that can offer competitive advantages, such as cost-effective pricing, reliable supply chains, and adherence to international quality standards, could position themselves as valuable partners.

2Requirements & Qualifications

Indian exporters seeking to supply Fosun Pharma USA and the U.S. market must obtain FDA approval for their products, demonstrating compliance with U.S. safety, efficacy, and quality standards. Manufacturers must adhere to GMP standards recognized by the FDA, ensuring consistent product quality. Additionally, products must meet FDA labeling requirements, including detailed information in English and compliance with serialization mandates. Establishing a reliable supply chain and maintaining transparency in manufacturing processes are also crucial for gaining and maintaining business relationships in the U.S. market.

How to Approach

Frequently Asked Questions — Fosun Pharma USA Inc

What products does Fosun Pharma USA Inc import from India?

Fosun Pharma USA Inc imports 2 pharmaceutical products across 2 categories. Top imports: Oxaliplatin ($250.0K), Cisplatin ($200.0K).

Who supplies pharmaceuticals to Fosun Pharma USA Inc from India?

Fosun Pharma USA Inc sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $428.3K).

What is Fosun Pharma USA Inc's total pharmaceutical import value?

Fosun Pharma USA Inc's total pharmaceutical import value from India is $450.0K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fosun Pharma USA Inc focus on?

Fosun Pharma USA Inc imports across 2 categories. The largest: Advanced Oncology (55.6%), Oncology (44.4%).

Get Full Fosun Pharma USA Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Cisplatin injection 100MG/100ML	$141.6K	3
Oxaliplatin INJ USP 100MG/20ML	$100.0K	2
Oxaliplatin injection 50MG/10ML 5MG/ML	$100.0K	2
Cisplatin injection 50MG/50ML	$50.0K	1
Oxaliplatin	$36.7K	1